- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 13: Final Thoughts on Clinical Diagnostic Tests
The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to, such as developing better systems to integrate clinical information with molecular data and increased FDA oversight.
The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to.
Bryan Loy, MD, MBA, is optimistic about the future, but recognizes that the issues of accountability and FDA governance are the least of the concerns in the area of diagnostic testing.
Daniel F. Hayes, MD, believes having more consistent regulations by making things harder will actually make things easier to get new markers out.
Francisco J. Esteva, MD, PhD, said better systems need to be developed to integrate the clinical information with molecular data to ensure patients get the appropriate care.
John L. Fox, MD, MHA, is also looking forward to increased FDA oversight, although he added that it will still remain to be seen whether the medical community can ensure the tests are used appropriately so the right patients receive the right treatment.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
